Patent protects Supera-CBD, a preclinical cannabidiol derivative that targets cannabinoid receptor type 2 for the treatment of neuroinflammatory and neurodegenerative… Read More…..
Excerpt only …
READ MORE BELOW
Source : MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds
reposted by Cannabis News World